Clinical trials: Antibody
COVID 19
COVID 19 Seroprevalence Amongst Healthcare Workers in JHAH
Healthcare workers play a critical role in fighting the pandemic, not only by managing the patients' health clinically, but also by implementing adequate measures for infection prevention and control in healthcare facilities.
- Trial name
- NCT04469647
- Testing
- Serology Test
- Where
- Saudi Arabia
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Aramco Healthcare
Leukaemia, Lymphocytic, Chronic
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
The purpose of this study is to determine whether HuMax-CD20 (ofatumumab) is effective in the treatment of patients failing both fludarabine and alemtuzumab.
- Trial name
- NCT00349349
- Testing
- ofatumumab
- Volunteers
- 223 people
- Sponsor
- GlaxoSmithKline
Graft Versus Host Disease, Steroid Refractory GVHD
Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Acute Graft Versus Host Disease (GVHD) is a serious medical condition that is a common development after Bone Marrow Transplant (BMT).
- Conditions
- Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease
- Trial name
- NCT01485055
- Testing
- Infliximab and Basiliximab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Nationwide Children's Hospital
Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection
A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Cytomegalovirus (CMV) is a common virus that usually presents with few if any side effects. When first infected, some people may have symptoms similar to mononucleosis (i.e., fatigue, weakness, fever, swollen glands).
- Trial name
- CMV (NCT01376778)
- Testing
- CMV hyperimmune globulin
- Where
- 16 sites in United States
- Volunteers
- 399 people, healthy volunteers welcome
- Sponsor
- The George Washington University Biostatistics Center
Common Variable Immune Deficiency, Specific Antibody Deficiency
Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older
Recommendations concerning the administration of Zostavax® in patients with antibody deficiency are unclear. The investigators plan to assess the immunogenicity and safety of Zostavax® in patients with antibody deficiency as…
- Conditions
- Common Variable Immune Deficiency, Specific Antibody Deficiency, X-linked Agammaglobulinemia
- Trial name
- NCT02960399
- Testing
- Zostavax®
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Hepatic Impairment, Cirrhosis
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of…
- Trial name
- NCT05484206
- Testing
- VIR-2218, VIR-3434
- Where
- 4 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
Subclinical Hypothyroidism, Autoimmune Thyroid Disease
NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease
Previously, studies have shown that children of women with thyroid autoantibodies experience more birth complications and poorer health in their first days.
- Conditions
- Subclinical Hypothyroidism, Autoimmune Thyroid Disease, Alteration of Mitochondrial Membrane
- Trial name
- NCT02061111
- Where
- Denmark
- Volunteers
- 77 people
- Sponsor
- Naestved Hospital
Sporadic Inclusion Body Myositis, Inclusion Body Myositis
Sporadic Inclusion Body Myositis Natural History Study
This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total).
- Trial name
- INSPIRE-IBM (NCT05046821)
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of California, Irvine
Hepatocellular Carcinoma
A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and tolerability of escalating doses of mapatumumab in combination with sorafenib in subjects with advanced Hepatocellular Carcinoma who are positive for hepatitis B surface…
- Trial name
- HCC (NCT00712855)
- Testing
- mapatumumab, sorafenib
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Pancreatic Neoplasm
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
This study aims to seek evidence that activation of certain cells of the immune system will be safe and well tolerated in combination with cytotoxic chemotherapy.
- Trial name
- NCT00711191
- Testing
- monoclonal antibody, chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Malignant Ascites
Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody
A Phase II, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of M701 in treating Patients with Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer combined with Systemic Therapy.
- Trial name
- NCT06266091
- Testing
- M701, paracentesis
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Primary Biliary Cholangitis, Intrahepatic Bile Duct Cancer
Patients With Primary Biliary Cholangitis
Primary biliary cholangitis (PBC) is a chronic autoimmune disease characterized by progressive destruction of the small intrahepatic bile ducts, leading to cholestasis and potential progression to cirrhosis.
- Conditions
- Primary Biliary Cholangitis, Intrahepatic Bile Duct Cancer, Cancer Liver
- Trial name
- BILIFLEX (NCT07573514)
- Testing
- Reflex AMA and ANA testing
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Colorectal Cancer
Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients
Objectives: 1. To estimate progression-free survival (PFS) at 12 months in subjects with metastatic colorectal cancer who receive FOLFIRI [folinic acid (leucovorin or LV), 5-Fluorouracil (5-FU), irinotecan) plus bevacizumab as…
- Trial name
- NCT00354978
- Testing
- 5-Fluorouracil, Bevacizumab, Leucovorin
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis
This is a phase 2, double-blind, randomized, controlled, multicenter trial evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of 2 VIS954 dosing regimens in patients with moderate to severe acute…
- Trial name
- NCT07904806
- Testing
- VIS954, Standard Of Care (SOC)
- Volunteers
- 75 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Diabetic Polyneuropathy
A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy
The main purpose of this study is to compare the change in pain intensity during treatment with a CGRP monoclonal antibody (eptinezumab) compared with placebo treatment in patients with painful diabetic polyneuropathy (DPN).
- Trial name
- NCT05937152
- Testing
- Eptinezumab
- Where
- 3 sites in United States, Denmark
- Sponsor
- Mayo Clinic
Immunoglobulin G Subclass 4 Related Disease, IgG4-related Disease
Treatment of IgG4-Related Disease With Revlimid and Rituximab
Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does combination therapy with rituximab and revlimid cause a sustained…
- Conditions
- Immunoglobulin G Subclass 4 Related Disease, IgG4-related Disease, Autoimmune Pancreatitis, IgG4-related Sclerosing Cholangitis
- Trial name
- TIGR2 (NCT02705638)
- Testing
- Rituximab, Lenalidomide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Psoriasis
AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects
Investigational drug AMG 714 will be given to 66 subjects with moderate to severe psoriasis to study safety, pharmacokinetics, and efficacy.
- Trial name
- NCT00443326
- Testing
- AMG 714
- Volunteers
- 22 people
- Sponsor
- Amgen
Gastric Cancer
Safety and Efficacy of NK510 to Treat Gastric Cancer
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer.NK510 will be administered in combination with PD-1 blockade or monoclonal anti-HER2 antibody.
- Trial name
- NCT06098898
- Testing
- NK510, Tislelizumab，atezolizumab or Trastuzumab
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants…
- Trial name
- NCT06842498
- Testing
- FG-3246
- Where
- 23 sites in United States
- Volunteers
- 75 people
- Sponsor
- Kyntra Bio
AQP4+ NMOSD
A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
The goal of this clinical trial is to find out if the investigational medicine BMS-986353 is safe and well tolerated in adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- NCT07573332
- Testing
- CC-97540 (BMS-986353), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Texas Southwestern Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.